Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Galmed Enters Manufacturing Agreement with Perrigo for Aramchol

galmedpharma

Israel’s Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced that it has entered into a Manufacturing Services Agreement with Irelands’ Perrigo API Ltd., a subsidiary of Perrigo Company plc, for the large-scale production of the active pharmaceutical ingredient (“API”) of Galmed’s product candidate, aramchol.

The company says that the API produced pursuant to this agreement is expected to provide sufficient quantities of aramchol for Galmed’s potential future Phase III clinical trials of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.

According to the terms of the agreement, Perrigo will provide manufacturing process optimization services for large-scale production of the aramchol API, manufacture the aramchol API pursuant to current good manufacturing processes, or cGMP, and perform additional development services regarding scale-up and manufacturing optimization for the aramchol API.

The agreement also provides Perrigo with the option to manufacture commercial supplies of the aramchol API in the future.

Galmed’s Chief Executive Officer, Allen Baharaff, stated, “we are delighted to partner with Perrigo, one of the world’s leading pharmaceutical manufacturers, for large-scale API production.” Mr. Baharaff continued, “we selected Perrigo as our API supplier because of its experience in cost-effective large-scale cGMP production of small molecule APIs. We believe that initiating the process of large-scale API production now may facilitate the commencement of our potential future Phase III clinical trials, assuming applicable regulatory approval to conduct the same, and provide preferential pricing, which we believe may ultimately provide a more affordable treatment option for NASH patients in the future.”

Perrigo develops, manufactures and distributes over-the-counter (“OTC”) and generic prescription pharmaceuticals, nutritional products and APIs, and receives royalties from the Multiple Sclerosis drug, Tysabri. It is the world’s largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo declares its mission is to offer uncompromised “Quality Affordable Healthcare Products” and it does so across a wide variety of product categories, primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

Business

Now Platika joins and elite club of $10 billion plus Israeli firms.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

Advertisement